Skip to main content

Absci Corporation (ABSI)

New York Stock Exchange Healthcare BiotechnologyView data quality →
30.4Poor

ValueMarkers Composite Index

Top 0%#44,612 of 44,714
Overvalued

9012% above intrinsic value ($0)

UndervaluedFair ValueOvervalued
Piotroski
3/9
Weak
Beneish
-0.58
High Risk
Altman
4.96
Safe
DCF Value
$0
Overvalued
ROIC
-63.9%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Absci Corporation (ABSI) — VMCI valuation read

Headline read on ABSI: VMCI of 30/100 versus a Healthcare sector median of 50. The 20-point below-median position is what makes Absci Corporation a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on ABSI: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on ABSI: value (ABSI trades at 15.0x earnings, 17% below the Healthcare median of 18.0x), quality (ROIC of 19.0% sits 9.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of -2.0x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

ABSI fell 2.7% over the trailing 7 days, with a -21.7% read on a 30-day basis.

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

CEO: Sean McClain156 employeesUSwww.absci.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in ABSI’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.